# Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)

> **NCT05672550** · PHASE4 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 50 (actual)

## Conditions studied

- Pediatric Kidney Transplant Recipients

## Interventions

- **DRUG:** Bayesian based dose adjustment of enoxaparin
- **DRUG:** Usual dose adjustment of enoxaparin

## Key facts

- **NCT ID:** NCT05672550
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-28
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-01-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05672550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05672550, "Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05672550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*